Viridian Therapeutics, Inc.\DE financial data

Symbol
VRDN on Nasdaq
Location
Waltham, MA
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 26 Feb 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1301% % -27%
Debt-to-equity 16% % 66%
Return On Equity -58% % -35%
Return On Assets -50% % -27%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 102,206,571 shares 25%
Common Stock, Shares, Outstanding 101,826,500 shares 26%
Entity Public Float $943,000,000 USD 29%
Common Stock, Value, Issued $1,018,000 USD 26%
Weighted Average Number of Shares Outstanding, Basic 66,420,063 shares 52%
Weighted Average Number of Shares Outstanding, Diluted 66,420,063 shares 52%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense $77,225,000 USD -1.6%
Operating Income (Loss) $363,395,000 USD -22%
Nonoperating Income (Expense) $20,794,000 USD -29%
Net Income (Loss) Attributable to Parent $342,601,000 USD -27%
Earnings Per Share, Basic -4.3 USD/shares 16%
Earnings Per Share, Diluted -4.3 USD/shares 16%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash, Cash Equivalents, and Short-term Investments $874,700,000 USD 22%
Assets, Current $894,233,000 USD 21%
Property, Plant and Equipment, Net $1,228,000 USD -0.65%
Operating Lease, Right-of-Use Asset $2,421,000 USD 9.8%
Other Assets, Noncurrent $1,536,000 USD 207%
Assets $899,418,000 USD 21%
Accounts Payable, Current $8,683,000 USD 305%
Employee-related Liabilities, Current $19,657,000 USD 85%
Accrued Liabilities, Current $62,013,000 USD 36%
Contract with Customer, Liability, Current $367,000 USD 27%
Liabilities, Current $70,696,000 USD 48%
Contract with Customer, Liability, Noncurrent $140,000 USD -67%
Operating Lease, Liability, Noncurrent $1,900,000 USD -5%
Other Liabilities, Noncurrent $2,341,000 USD 1.4%
Liabilities $177,251,000 USD 150%
Accumulated Other Comprehensive Income (Loss), Net of Tax $447,000 USD
Retained Earnings (Accumulated Deficit) $1,338,458,000 USD -34%
Stockholders' Equity Attributable to Parent $722,167,000 USD 7.5%
Liabilities and Equity $899,418,000 USD 21%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $92,653,000 USD -105%
Net Cash Provided by (Used in) Financing Activities $9,212,000 USD -95%
Net Cash Provided by (Used in) Investing Activities $100,062,000 USD
Common Stock, Shares Authorized 200,000,000 shares 0%
Common Stock, Shares, Issued 101,826,500 shares 26%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $16,621,000 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $212,382,000 USD 113%
Interest Paid, Excluding Capitalized Interest, Operating Activities $448,000 USD -0.88%
Deferred Tax Assets, Valuation Allowance $316,823,000 USD 52%
Deferred Tax Assets, Gross $316,823,000 USD 52%
Operating Lease, Liability $2,712,000 USD 6.9%
Payments to Acquire Property, Plant, and Equipment $86,000 USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $342,144,000 USD -27%
Lessee, Operating Lease, Liability, to be Paid $3,159,000 USD 2.6%
Property, Plant and Equipment, Gross $2,444,000 USD -2.3%
Operating Lease, Liability, Current $753,000 USD 47%
Lessee, Operating Lease, Liability, to be Paid, Year Two $836,000 USD 12%
Lessee, Operating Lease, Liability, to be Paid, Year One $965,000 USD 33%
Operating Lease, Weighted Average Discount Rate, Percent 0.092 pure -1.1%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $447,000 USD -18%
Lessee, Operating Lease, Liability, to be Paid, Year Three $854,000 USD 39%
Deferred Tax Assets, Operating Loss Carryforwards $123,892,000 USD 60%
Preferred Stock, Shares Authorized 5,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four $504,000 USD -20%
Additional Paid in Capital $1,927,104,000 USD 30%
Depreciation, Depletion and Amortization $117,000 USD -19%
Deferred Tax Assets, Net of Valuation Allowance $0 USD
Share-based Payment Arrangement, Expense $44,303,000 USD 5.1%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%